Jeffrey Friedland, will be a panelist at the CannaTech Cannabis Innovation Summit being held in Tel Aviv, Israel from March 7-9.
Friedland will be a panelist in a session entitled, “The Cannabis Climate: Investment Trends and Forecasts.” Other panelists include Brendan Kennedy, CEO of Privateer Holdings, Inc.; Rafi Cohen, Head of Israel Operations for the Alta Fund; Ayelet Torem, a partner with APM Law; and Scott Greiper, President of Viridian Capital Advisors LLC.
The CannaTech Cannabis Innovation Summit is the premier international platform for accelerating strategic alliances and technological developments in the cannabis industry. It will provide a dynamic platform for entrepreneurs, researchers and investors, along with pharma, agritech and technology entrepreneurs and other stakeholders to connect and learn about opportunities and the latest cannabis technology and research.
The Summit will be chaired by Professor Raphael Mechoulam, considered the "father of cannabinoid research.” Professor Mechoulam conducted studies that established the foundation for the entire field of cannabis research.
Widely acknowledged as the “cannabis superpower,” Israel is the world leader in advanced medical cannabis policy, medical cannabis research, cannabis breeding, plant sciences and medical cannabis delivery systems. The country’s proactive regulatory system facilitates patient access to cannabis for medical use and enables major medical institutions to conduct clinical studies.
CNN medical correspondent Dr. Sanjay Gupta described Israel as “the medical marijuana research capital” in his documentary “Weed,” and dedicated a portion of the CNN program to Israel’s advances in cannabis research. Gupta was amazed to see how seamlessly Israel had integrated cannabis into its health-care system.
About Professor Raphael Mechoulam
Professor Raphael Mechoulam is credited with discovering THC, and the endocannabinoid system, and viewed by many as the most influential figure in the field of medical cannabis research. He is an organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem. Professor Mechoulam received his M.Sc. in biochemistry from the Hebrew University of Jerusalem in 1952 and his Ph.D. at the Weizmann Institute in 1958. He completed his postdoctoral research at the Rockefeller Institute.
In 1963, Professor Mechoulam isolated cannabidiol (CBD), the compound that research indicates is a key to many of the medical properties of cannabis. A year later, Mechoulam and his team were the first scientisat to isolate tetrahydrocannabinol (THC), the main physiologically active compound in cannabis, which is responsible for the plant’s consciousness-altering effects. Twenty years later, Mechoulam and his team concluded that THC interacts with the largest receptor system in the human body, the endocannabinoid system. He then found that the human brain produces its very own form of cannabis – a chemical that they named anandamide after the Sanskrit word ananda, translated as bliss.
Professor Mechoulam has received over 25 academic awards including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012 for his medical cannabis research.
About Jeffrey Friedland
Jeffrey Friedland is an emerging market pioneer -- his firm, Friedland Global Capital, was one of the first American investment banks to establish a presence in China -- and is now on the forefront of the global cannabis industry. In his book, Marijuana, the World's Most Misunderstood Plant, he dives into the world of medical marijuana, discussing what we know and what we still hope to discover. The book is available at Amazon in print and Kindle editions.
Until early 2016, Mr. Friedland was an owner of two retail cannabis stores in Colorado located in the mountain resort towns of Breckenridge and Crested Butte, and a cannabis cultivation facility south of Steamboat Springs, which were featured in CNN's 2015 reality series, High Profits.
He is also CEO of INTIVA Inc., a multi-faceted life sciences company in the worldwide legal cannabis industry. INTIVA has established operating businesses and made venture investments in California, Colorado, Canada and Israel.
Mr. Friedland is a director of Israel-based, Israel Plant Sciences Ltd., a company that was formed to participate in Israel’s innovative agriculture and medicinal plant sectors and other agricultural related technologies.
He is an adviser to the U.S. based, private equity fund, First Harvest Financial, a firm focused on cannabis investments in the U.S. and globally.
Mr. Friedland has been the chief executive officer and a director of a NASDAQ listed financial services company, a director and chairman of the audit committee of a New York Stock Exchange-listed company, and chairman of a company listed on the EU regulated market of the Frankfurt Stock Exchange.
He has been featured or quoted in numerous publications including the Wall Street Journal, USA Today, Forbes, and the South China Morning Post and has been a regular contributor to Money China, an official publication of the Chinese government.
Friedland Global Capital Contact:
Tel. 1 647 800 1280
Author Page at Amazon: www.amazon.com/author/jeffreyfriedland
Visit CannaTech’s website for information about the CannaTech Cannabis Innovation Summit, including the participants and full schedule.